ReachMD

Episodes 1-15 of 15

• 1

  

  RestartResume

  HER3-Directed ADCs in Lung Cancer

  HER3-Directed ADCs in Lung Cancer

  1.00 program credits
• 1

  

  RestartResume

  HER2-Directed ADCs in Gastric Cancer

  HER2-Directed ADCs in Gastric Cancer

  1.00 program credits
• 1

  

  RestartResume

  HER3-Directed ADCs in Breast Cancer

  HER3-Directed ADCs in Breast Cancer

  1.00 program credits

• • 

    

    Jaffer Ajani, MD

    Peer

  • 

    

    Justin Gainor, MD

    Peer

  • 

    

    Sara A. Hurvitz, MD, FACP

    Peer

  • 

    

    Gopa Iyer, MD

    Peer

  3

  

  A Deep Dive into the Management of AEs Associated with ADCs

  1.00 credits 9 episodes
• 3

  

  RestartResume

  HER2-Directed ADCs in Breast Cancer

  HER2-Directed ADCs in Breast Cancer

  1.00 program credits
• 1

  

  RestartResume

  TROP2-Directed ADCs in Bladder Cancer

  TROP2-Directed ADCs in Bladder Cancer

  1.00 program credits
• 1

  

  RestartResume

  TROP2-Directed ADCs in Lung Cancer

  TROP2-Directed ADCs in Lung Cancer

  1.00 program credits
• 2

  

  RestartResume

  Nectin-4-Directed ADCs in Bladder Cancer

  Nectin-4-Directed ADCs in Bladder Cancer

  1.00 program credits
• 1

  

  RestartResume

  HER2-Directed ADCs in Lung Cancer

  HER2-Directed ADCs in Lung Cancer

  1.00 program credits
• 1

  

  RestartResume

  TROP2-Directed ADCs in Breast Cancer

  TROP2-Directed ADCs in Breast Cancer

  1.00 program credits

• • 

    

    Jonathan C. Routh, MD, MPH, FAAP

    Peer

  • 

    

    Benjamin M. Whittam, MD, MS, FAAP, FACS

    Peer

  5

  

  RestartResume

  Advances in the Treatment of Neurogenic Detrusor Overactivity

  Advances in the Treatment of Neurogenic Detrusor Overactivity

  0.50 credits

• • 

    

    Daniel P. Petrylak, MD

    Peer

  • 

    

    Arlene O. Siefker-Radtke, MD

    Peer

  6

  

  RestartResume

  Keeping Pace in Bladder Cancers: All About Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma

  Keeping Pace in Bladder Cancers: All About Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma

  0.25 credits

• • 

    

    Lauren Ritterhouse, MD ,PhD

    Peer

  • 

    

    Pasi Antero Jänne, MD, PhD

    Peer

  • 

    

    Kanwal Raghav, MD

    Peer

  2

  

  RestartResume

  The Role of HER3 Expression in Advanced Solid Tumors

  The Role of HER3 Expression in Advanced Solid Tumors

  0.50 credits

• • 

    

    Johann de Bono, MD, PhD

    Peer

  • 

    

    Alicia K. Morgans, MD, MPH

    Peer

  3

  

  RestartResume

  Keeping Pace in GU Cancers: Clinical Considerations for Prostate Cancer – Global Perspectives

  Keeping Pace in GU Cancers: Clinical Considerations for Prostate Cancer – Global Perspectives

  0.25 credits

• • 

    

    Arjun V. Balar, MD

    Peer

  • 

    

    Daniel P. Petrylak, MD

    Peer

  1

  

  RestartResume

  State of the Union: Advances in the Management of mUC

  State of the Union: Advances in the Management of mUC

  0.50 credits